Docoh
Loading...
Sign up Log in

WST West Pharmaceutical Services

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Company profile

Ticker
WST
Exchange
NYSE
Website
www.westpharma.com/
CEO
Eric Green
Employees
Incorporated
Pennsylvania
Location
Pennsylvania
Fiscal year end
Dec 31
Sector
Health Care and Social Assistance > Medical Laboratories
Industry (SIC)
Fabricated Rubber Products, NEC
Carlisle Companies • Omnova Solutions • Yunhong CTI • Vystar • Allied Security Innovations ...
Former names
WEST CO INC
SEC CIK
0000105770
Corporate docs
IRS number
231210010

WST stock data

(
)

News

Pro users get this 30m faster
Analyzing The Price Action In West Pharmaceutical Servs Stock Today
18 Feb 21
West Pharmaceutical Servs's Stock Price And Volume Action West Pharmaceutical Servs's (NYSE:WST) stock is trading up 2.28% to a price of $301.24. The stock's volume is currently 49.59 thousand, which is roughly 9.64% of its recent 30-day volume average of 514.25 thousand.
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout
18 Feb 21
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17)
West Pharmaceutical: Q4 Earnings Insights
18 Feb 21
Shares of West Pharmaceutical Servs (NYSE:WST) moved higher by 0.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 63.41% year over year to $1.34, which beat the estimate of $1.12.
West Pharmaceutical Servs Q4 EPS $1.34 Beats $1.12 Estimate, Sales $580.20M Beat $543.67M Estimate
18 Feb 21
Earnings Scheduled For February 18, 2021
18 Feb 21

Press releases

Pro users get this 30m faster
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of West Pharmaceutical Services, Inc. (WST)
31 Mar 21
New York, New York--(Newsfile Corp. - March 31, 2021) - Levi & Korsinsky announces it has commenced an investigation of West Pharmaceutical Services, Inc. (NYSE:WST) concerning possible breaches of fiduciary duty.
West Announces Participation in Upcoming Investor Conference
17 Mar 21
EXTON, Pa., March 17, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) announced that management will present virtually at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum at
West Announces Second-Quarter 2021 Dividend
24 Feb 21
EXTON, Pa., Feb. 24, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of
West Pharmaceutical Services, Inc. to Host Earnings Call
18 Feb 21
West Announces Fourth-Quarter and Full-Year 2020 Results
18 Feb 21

Calendar

23 Feb 21
12 Apr 21
31 Dec 21

Financial summary

Financial statements Chart WST financial data
Quarter (USD)
 Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Recent insider trades

WST insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Mar 21 Chad Winters Common Stock Grant Aquire A No No 261.62 170 44.48K 714.887
26 Feb 21 Silji Abraham Common Stock Payment of exercise Dispose F No No 280.65 677 190K 8,248.3
23 Feb 21 Silji Abraham Stock Options Common Stock Grant Aquire A No No 274.29 4,364 1.2M 4,364
23 Feb 21 Favorite Annette F Stock Options Common Stock Grant Aquire A No No 274.29 3,968 1.09M 3,968
23 Feb 21 Quintin J Lai Stock Options Common Stock Grant Aquire A No No 274.29 2,776 761.43K 2,776
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

WST institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

93.1% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 576 561 +2.7%
Opened positions 84 100 -16.0%
Closed positions 69 50 +38.0%
Increased positions 233 193 +20.7%
Reduced positions 191 207 -7.7%
13F shares
 Current Prev Q Change
Total value 19.47B 18.55B +5.0%
Total shares 68.74M 67.55M +1.8%
Total puts 72.2K 25K +188.8%
Total calls 59.5K 72.7K -18.2%
Total put/call ratio 1.2 0.3 +252.9%
Largest owners
 Shares Value Change
Vanguard 8.29M $2.35B -3.7%
BLK Blackrock 7.29M $2.07B +5.1%
TROW T. Rowe Price 4.62M $1.31B +3.9%
BEN Franklin Resources 3.85M $1.09B -1.7%
STT State Street 3.35M $948.3M -3.8%
IVZ Invesco 1.73M $488.97M +12.4%
ATAC Neuberger Berman 1.64M $464.52M -14.4%
WCM Investment Management 1.61M $457.08M +17.5%
Bamco 1.34M $378.24M -7.2%
Artisan Partners Limited Partnership 1.3M $368.6M -4.2%
Largest transactions
 Shares Bought/sold Change
Norges Bank 745.96K +745.96K NEW
APG Asset Management 1.19M +680.09K +133.2%
1832 Asset Management 0 -482.2K EXIT
FMR 1.18M +376.26K +46.9%
BLK Blackrock 7.29M +350.91K +5.1%
Vanguard 8.29M -317.92K -3.7%
ATAC Neuberger Berman 1.64M -277.34K -14.4%
WCM Investment Management 1.61M +240.41K +17.5%
Carillon Tower Advisers 202.15K +202.15K NEW
Brown Advisory 1.17M +196.95K +20.2%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Insulet
Management Discussion
  • Consolidated net sales increased by $307.0 million, or 16.7%, in 2020, including a favorable foreign currency translation impact of $5.7 million. Excluding foreign currency translation effects, as well as incremental sales of $1.2 million from the acquisition of our distributor in South Korea in 2019, consolidated net sales increased by $300.1 million, or 16.3%.
  • Proprietary Products – Proprietary Products net sales increased by $250.0 million, or 17.9%, in 2020, including a favorable foreign currency translation impact of $2.2 million. Excluding foreign currency translation effects, as well as $1.2 million of incremental sales in 2020 from the acquisition of our distributor in South Korea in 2019, net sales increased by $246.6 million, or 17.6%, primarily due to growth in our high-value product offerings, including our FluroTec-coated components, Westar® components, Daikyo® and NovaPure® components, Daikyo Crystal Zenith® products, and our self-injection delivery platforms, all of which included approximately $99 million in COVID-19 related activity for vaccines, antiviral treatments and treatment of underlying COVID-19 symptoms.
  • Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $57.1 million, or 12.9%, in 2020, including a favorable foreign currency translation impact of $3.5 million. Excluding foreign currency translation effects, net sales increased by $53.5 million, or 12.1%, due to an increase in the sale of healthcare-related injection and diagnostic devices.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: abuse, admixture, aforesaid, Amneal, antiviral, attrition, AZ, Bangalore, catalog, Cayey, centrally, Chad, CODM, collaborative, color, compel, consulting, convinced, Council, dedicated, diligence, distancing, downside, driven, duration, employment, England, ethical, facilitate, FCA, fluid, foster, found, gender, gowning, guide, HSE, imposed, improper, inclusion, inclusive, India, inspection, job, Kimberly, learning, lifetime, linking, live, MacKay, Maker, mask, matrix, member, mental, metric, mission, notably, online, optimize, organizational, partnership, percent, persuade, phase, Phoenix, precautionary, premium, proactive, progression, proud, receipt, remote, resource, reward, Scottsdale, screening, Segal, situation, slightly, specialty, spread, stronger, strongly, submit, tracked, trained, training, tuition, UGI, unforeseeable, upside, vision, women, workplace
Removed: absolute, achieving, Affordable, AG, backlog, began, Bolivar, Commonwealth, confirmation, consist, curtailment, deconsolidation, derecognition, discrete, division, dual, Eastman, expand, faulty, filled, George, governed, half, immaterial, Ireland, Kodak, leasing, making, Manager, mandatory, mechanism, methodology, Miller, mistake, nonfinancial, official, Ortho, party, positively, PPACA, previously, referendum, renew, rental, repeal, Resnick, seasonal, simple, spending, Sri, streamlined, substantially, Tech, termination, translating, Venezuela, Venezuelan, volume, Waterford
From filing 10-K 2020 FY

Financial reports

View all
10-K
2020 FY
Annual report
23 Feb 21
10-Q
2020 Q3
Quarterly report
23 Oct 20
10-Q
2020 Q2
Quarterly report
24 Jul 20
10-Q
2020 Q1
Quarterly report
24 Apr 20
10-K
2019 FY
Annual report
23 Feb 20
10-Q
2019 Q3
Quarterly report
28 Oct 19
10-Q
2019 Q2
Quarterly report
29 Jul 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
30 Oct 18

Current reports

View all
8-K
Departure of Directors or Certain Officers
1 Mar 21
8-K
West Announces Fourth-Quarter and Full-Year 2020 Results
18 Feb 21
8-K
West Announces First-Quarter 2021 Dividend, 2021 Share Repurchase Program and Participation in Upcoming Investor Conference
9 Dec 20
8-K
West Appoints Kimberly Banks MacKay as Senior Vice President General Counsel and Corporate Secretary
9 Nov 20
8-K
West Announces Increase to Fourth-Quarter 2020 Dividend
28 Oct 20
8-K
West Announces Third-Quarter 2020 Results
22 Oct 20
8-K
West Announces Second-Quarter 2020 Results
23 Jul 20
8-K
West Announces Third Quarter 2020 Dividend
15 Jul 20
8-K
Departure of Directors or Certain Officers
7 May 20
8-K
West Announces First-Quarter 2020 Results
23 Apr 20

Registration and prospectus

View all
S-8
Registration of securities for employees
2 May 16
SC TO-I/A
Issuer tender offer statement (amended)
5 Jun 12
SC TO-I/A
Issuer tender offer statement (amended)
3 Jun 12
SC TO-C
Information about tender offer
7 May 12
SC TO-I
Issuer tender offer statement
7 May 12
S-8
Registration of securities for employees
11 May 11
S-8
Registration of securities for employees
28 Dec 10
S-8
Registration of securities for employees
29 Dec 08
424B7
Prospectus with selling stockholder info
27 Feb 08
S-3ASR
Automatic shelf registration
6 Aug 07

Proxies

View all
DEFA14A
Additional proxy soliciting materials
24 Mar 21
DEF 14A
Definitive proxy
24 Mar 21
DEFA14A
Additional proxy soliciting materials
17 Apr 20
DEFA14A
Additional proxy soliciting materials
25 Mar 20
DEF 14A
Definitive proxy
25 Mar 20
PRE 14A
Preliminary proxy
13 Mar 20
DEFA14A
Additional proxy soliciting materials
22 Mar 19
DEF 14A
Definitive proxy
22 Mar 19
DEF 14A
Definitive proxy
20 Mar 18
DEFA14A
Additional proxy soliciting materials
20 Mar 18

Other

View all
SD
Conflict minerals disclosure
28 May 20
SD
Conflict minerals disclosure
30 May 19
CT ORDER
Confidential treatment order
20 Aug 18
SD
Conflict minerals disclosure
25 May 18
SD
Conflict minerals disclosure
25 May 17
CT ORDER
Confidential treatment order
16 Mar 17
CT ORDER
Confidential treatment order
5 Dec 16
CT ORDER
Confidential treatment order
14 Sep 16
SD
Conflict minerals disclosure
26 May 16
SD
Conflict minerals disclosure
31 May 15

Ownership

View all
4
WEST PHARMACEUTICAL SERVICES / Chad Winters ownership change
19 Mar 21
4
WEST PHARMACEUTICAL SERVICES / Silji Abraham ownership change
1 Mar 21
4
WEST PHARMACEUTICAL SERVICES / Bernard Birkett ownership change
25 Feb 21
4
WEST PHARMACEUTICAL SERVICES / Chad Winters ownership change
25 Feb 21
4
WEST PHARMACEUTICAL SERVICES / DAVID A MONTECALVO ownership change
25 Feb 21
4
WEST PHARMACEUTICAL SERVICES / Kimberly Banks MacKay ownership change
25 Feb 21
4
WEST PHARMACEUTICAL SERVICES / Quintin J Lai ownership change
25 Feb 21
4
WEST PHARMACEUTICAL SERVICES / Annette F Favorite ownership change
25 Feb 21
4
WEST PHARMACEUTICAL SERVICES / Silji Abraham ownership change
25 Feb 21
4
WEST PHARMACEUTICAL SERVICES / Eric Mark Green ownership change
25 Feb 21

Patents

View all
GRANT
Utility
Apparatuses for securing components of a drug delivery system during transport and methods of using same
30 Mar 21
An assembly of a drug delivery system, comprising: a first component; a second component which is configured to move linearly with respect to the first component; and, a resistance element configured to resist linear movement during transport of the first component with respect to the second component in a closed transport configuration but which is adapted to be overcome during nominal operation of the drug delivery system.
APP
Utility
Elastomer Articles Having Embedded Electronics and Method of Manufacturing the Same
25 Mar 21
A method of manufacturing a medical component includes preparing a first sheet of an elastomeric material, arranging at least one electronic device in the first sheet of elastomeric material to obtain an elastomeric preform, and arranging the elastomeric preform in a mold and molding the elastomeric preform therein to cure the elastomeric material and form the medical component having the at least one electronic device embedded therein.
GRANT
Utility
User actuated liquid drug transfer devices for use in ready-to-use (RTU) liquid drug transfer assemblages
16 Mar 21
Liquid drug transfer device for use in a Ready-To-Use liquid drug transfer assemblage for establishing flow communication between a liquid source and an injection vial.
GRANT
Utility
Detection and communication of plunger position using induction
16 Mar 21
A syringe system, including a plunger, a microcontroller, a battery, and a coil.
GRANT
Utility
Noise and vibration dampening mounting module for injector
23 Feb 21
An independent mounting module is receivable within a housing of an injector configured to dispense a substance from a cartridge insertable into the housing through an injection needle of the injector.

Transcripts

View all
2020 Q4
Earnings call transcript
18 Feb 21
2020 Q3
Earnings call transcript
22 Oct 20
2020 Q2
Earnings call transcript
23 Jul 20
2020 Q1
Earnings call transcript
23 Apr 20
2019 Q4
Earnings call transcript
13 Feb 20
2019 Q3
Earnings call transcript
24 Oct 19
2019 Q2
Earnings call transcript
25 Jul 19
2019 Q1
Earnings call transcript
25 Apr 19
2018 Q4
Earnings call transcript
14 Feb 19
2018 Q3
Earnings call transcript
25 Oct 18

Reddit threads

View all